Private demand for shingles vaccinations in the United Kingdom has more than doubled over the past year, driven in part by unproven claims that the vaccine may reduce the risk of developing dementia. The pharmacist chain Boots reported a 30 percent increase in bookings during the year ending last September, followed by a further doubling in the twelve months leading up to this month.

Shingles, a viral infection caused by the reactivation of the varicella-zoster virus— the same virus responsible for chickenpox— leads to a painful, blistering rash. Severe cases can result in secondary infections, neurological complications, and persistent pain lasting for months. The Shingrix vaccine, produced by GlaxoSmithKline, offers protection against shingles for more than ten years. It is provided free of charge by the National Health Service (NHS) to individuals aged 65 and older. However, people aged 50 and over can access the vaccine privately, at a cost of up to £460 for the recommended two doses.

Interest in the vaccine's potential impact on dementia grew following a 2022 study led by Stanford University. This research compared groups based on eligibility for the vaccine, determined by birth date restrictions, and reported that vaccination was associated with up to a 20 percent reduction in the risk of new dementia diagnoses. Despite the excitement generated by these findings, later research has challenged the validity of this potential benefit.

An analysis published earlier this year, which examined medical records for 6.3 million patients in England, found no evidence linking the shingles vaccine to decreased dementia risk. Experts have highlighted concerns regarding observational studies like Stanford’s, cautioning that they may be susceptible to biases that affect their reliability. Alasdair Munro, a lecturer specializing in vaccine clinical trials at Southampton University, noted that such research does not provide conclusive proof and should be interpreted carefully.

While the Shingrix vaccine remains an effective measure against shingles, medical professionals urge the public to recognize that its use as a dementia-prevention tool is not currently supported by robust evidence. The surge in private vaccinations reflects growing public interest but underscores the need for further scientific investigation to clarify any long-term cognitive benefits.